

## **Cancer Immunotherapy - A Global Market Overview**

Market Report | 2024-11-05 | 256 pages | Industry Experts

### **AVAILABLE LICENSES:**

- Single user licence (PDF) \$4500.00
- Enterprise Electronic (PDF) \$7200.00

### **Report description:**

#### **Cancer Immunotherapy Market Trends and Outlook**

Cancer immunotherapy, called immuno-oncotherapy, harnesses the body's immune system to identify and eliminate cancer cells. In contrast to traditional therapies like chemotherapy and radiation, which directly target cancer cells, immunotherapy enhances the immune response by utilizing tumor antigens that activate immune recognition. Monoclonal antibodies identify and tag cancer cells for elimination, while immune checkpoint inhibitors enhance the immune system's attack on tumors. Additionally, oncolytic viral therapies and cancer vaccines aim to destroy cancer cells or train the immune system to detect and attack cancer antigens more effectively. The effectiveness of these therapies varies across different cancer types, making them a significant focus in oncology research.

The global market for Cancer Immunotherapy is estimated at US\$135.2 billion in 2024 and is anticipated to post a CAGR of 9.8% during the 2024-2030 analysis period and stand at a projected US\$236.9 billion by 2030.

The global cancer immunotherapy market is primarily driven by the rising prevalence of cancer worldwide, leading to a growing demand for more effective treatment options. Oncolytic viral therapies and cancer vaccines use viruses to specifically target and destroy cancer cells, while Checkpoint inhibitors and CAR-T cell therapies are increasingly employed to treat lung cancer and melanoma. These therapies stimulate immune responses and are gaining attention due to their precise targeting and reduced side effects, further driving market demand. Advancements in biotechnology, including gene editing and bioinformatics, have enabled the development of personalized and efficient therapies. Additionally, investments in research and development and a supportive regulatory environment have accelerated the introduction of innovative treatments.

#### **Cancer Immunotherapy Regional Market Analysis**

North America dominates the market and is expected to hold an estimated share of 43.7% in 2024, primarily due to the increasing demand for advanced treatment options, a strong presence of major market players, and substantial investments in research and development. The United States leads this growth with favorable reimbursement policies and advanced healthcare infrastructure, which facilitates the adoption of immunotherapies. On the other hand, the Asia Pacific region is poised to be the fastest-growing market, with a projected CAGR of 11.3% during the forecast period 2024-2030. This growth is driven by a rising population of cancer patients, increased healthcare expenditures, and a growing awareness of innovative therapies in countries such as China and India. Government efforts to enhance healthcare infrastructure and a growing private sector are further driving this expansion, addressing the critical need for effective cancer treatments in both regions.

#### **Cancer Immunotherapy Market Analysis by Product**

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

The Monoclonal Antibodies segment dominates the cancer immunotherapy market, holding a projected share of 55.9% in 2024. This dominance is driven by growing R&D investments in bispecific, conjugated, and naked antigen-binding antibodies, which have created new growth opportunities in oncology therapeutics. These antibodies enhance adaptive immunity and specifically target cancer antigens, resulting in improved therapeutic outcomes with reduced side effects. In contrast, the Oncolytic Viral Therapies and Cancer Vaccines segment is expected to be the fastest-growing, with a projected CAGR of 11.8% during the analysis period 2024-2030, despite facing challenges like immunogenicity and immunosuppression in tumor environments.

#### Cancer Immunotherapy Market Analysis by Application

The lung cancer application is anticipated to maintain its dominant position by holding the largest market share of 13.8% in 2024. This growth is driven by the increasing prevalence of lung cancer, primarily due to increased smoking and the popularity of harmful products such as e-cigarettes. As the leading cause of cancer-related deaths globally, lung cancer requires immunotherapy treatments to manage the advanced stages of the disease. Meanwhile, the breast cancer application is expected to be the fastest-growing segment, with a projected CAGR of 13.5% during the forecast period 2024-2030, driven by the high prevalence of breast cancer, ongoing research and development efforts, and increased investments by leading players to develop novel therapeutics. The rising number of breast cancer cases among women globally further fuels this segment's expansion.

#### Cancer Immunotherapy Market Analysis by End-User

The Hospitals & Clinics segment is the largest end-user market, with an estimated share of 49.8% in 2024, primarily driven by the rising incidence of cancer, increased treatment rates, improved awareness, and the availability of immunotherapy treatments across numerous hospitals. The segment's significance is further strengthened by the growing number of hospital admissions for cancer treatment and the increased adoption of advanced therapies. Conversely, the Cancer Research Centers segment is anticipated to record the fastest growth with a CAGR of 10.9% during the analysis period from 2024 to 2030. This growth is driven by increasing investments in cancer research from corporate and government organizations, along with advancements in immunotherapy treatments.

#### Cancer Immunotherapy Market Report Scope

This global report on Cancer Immunotherapy analyzes the market based on product, application, and end-users. In addition to providing profiles of major companies operating in this space, the latest corporate and industrial developments have been covered to offer a clear panorama of how and where the market is progressing.

#### Key Metrics

Historical Period: 2021-2023

Base Year: 2023

Forecast Period: 2024-2030

Units: Value market in US\$

Companies Mentioned: 10+

#### Cancer Immunotherapy Market by Geographic Region

- North America (The United States, Canada, and Mexico)
- Europe (Germany, France, United Kingdom, Italy, Spain, and Rest of Europe)
- Asia-Pacific (Japan, China, India, South Korea, and Rest of Asia-Pacific)
- South America (Brazil, Argentina, and Rest of South America)
- Rest of World

#### Cancer Immunotherapy Market by Product

- Monoclonal Antibodies
- Oncolytic Viral Therapies & Cancer Vaccines
- Checkpoint Inhibitors & Immunomodulators

#### Cancer Immunotherapy Market by Application

- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Skin Cancer

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- Prostate Cancer
  - Stomach Cancer
  - Head & Neck Cancer
  - Others (Including Blood, Ovarian, Cervical, Kidney, Liver, Bladder, Pancreatic, and other cancers)
- Cancer Immunotherapy Market by End-User
- Hospitals & Clinics
  - Cancer Research Centers
  - Other End-Users (Including Ambulatory Surgical Centers (ASCs), and Homecare settings)

## **Table of Contents:**

### **PART A: GLOBAL MARKET PERSPECTIVE**

#### **1. INTRODUCTION**

- Product Outline
- Cancer Immunotherapy Defined
- Cancer Immunotherapy Products
  - o□Monoclonal Antibodies
  - o□Oncolytic Viral Therapies & Cancer Vaccines
  - o□Checkpoint Inhibitors & Immunomodulators
- Cancer Immunotherapy Applications
  - o□Lung Cancer
  - o□Breast Cancer
  - o□Colorectal Cancer
  - o□Skin Cancer
  - o□Prostate Cancer
  - o□Stomach Cancer
  - o□Head & Neck Cancer
  - o□Others (Including Blood, Ovarian, Cervical, Kidney, Liver, Bladder, Pancreatic, and other cancers)
- Cancer Immunotherapy End-Users
  - o□Hospitals & Clinics
  - o□Cancer Research Centers
  - o□Other End-Users (Including Ambulatory Surgical Centers (ASCs), and Homecare settings)

#### **2. Key Market Trends**

#### **3. Key Global Players**

- Amgen Inc.
- AstraZeneca plc
- Bayer AG
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- F. Hoffmann-La Roche AG
- GSK Plc
- Immunocore Holdings Plc
- Johnson & Johnson Innovative Medicine
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.

#### **4. Key Business & Product Trends**

#### **5. Global Market Overview**

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Global Cancer Immunotherapy Market Overview by Product
  - o□Cancer Immunotherapy Product Market Overview by Global Region
- Monoclonal Antibodies
- Oncolytic Viral Therapies & Cancer Vaccines
- Checkpoint Inhibitors & Immunomodulators
- Global Cancer Immunotherapy Market Overview by Application
  - o□Cancer Immunotherapy Application Market Overview by Global Region
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Skin Cancer
- Prostate Cancer
- Stomach Cancer
- Head & Neck Cancer
- Others
- Global Cancer Immunotherapy Market Overview by End-User
  - o□Cancer Immunotherapy End-User Market Overview by Global Region
- Hospitals & Clinics
- Cancer Research Centers
- Other End-Users

## PART B: REGIONAL MARKET PERSPECTIVE

Global Cancer Immunotherapy Market Overview by Geographic Region

### REGIONAL MARKET OVERVIEW

#### 6. North America

- North American Cancer Immunotherapy Market Overview by Geographic Region
- North American Cancer Immunotherapy Market Overview by Product
- North American Cancer Immunotherapy Market Overview by Application
- North American Cancer Immunotherapy Market Overview by End-User
- Country-wise Analysis of North American Cancer Immunotherapy Market
  - o□The United States
    - United States Cancer Immunotherapy Market Overview by Product
    - United States Cancer Immunotherapy Market Overview by Application
    - United States Cancer Immunotherapy Market Overview by End-User
  - o□Canada
    - Canadian Cancer Immunotherapy Market Overview by Product
    - Canadian Cancer Immunotherapy Market Overview by Application
    - Canadian Cancer Immunotherapy Market Overview by End-User
  - o□Mexico
    - Mexican Cancer Immunotherapy Market Overview by Product
    - Mexican Cancer Immunotherapy Market Overview by Application
    - Mexican Cancer Immunotherapy Market Overview by End-User

#### 7. Europe

- European Cancer Immunotherapy Market Overview by Geographic Region
- European Cancer Immunotherapy Market Overview by Product
- European Cancer Immunotherapy Market Overview by Application
- European Cancer Immunotherapy Market Overview by End-User
- Country-wise Analysis of European Cancer Immunotherapy Market

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

o Germany

- German Cancer Immunotherapy Market Overview by Product
- German Cancer Immunotherapy Market Overview by Application
- German Cancer Immunotherapy Market Overview by End-User

o France

- French Cancer Immunotherapy Market Overview by Product
- French Cancer Immunotherapy Market Overview by Application
- French Cancer Immunotherapy Market Overview by End-User

o The United Kingdom

- United Kingdom Cancer Immunotherapy Market Overview by Product
- United Kingdom Cancer Immunotherapy Market Overview by Application
- United Kingdom Cancer Immunotherapy Market Overview by End-User

o Italy

- Italian Cancer Immunotherapy Market Overview by Product
- Italian Cancer Immunotherapy Market Overview by Application
- Italian Cancer Immunotherapy Market Overview by End-User

o Spain

- Spanish Cancer Immunotherapy Market Overview by Product
- Spanish Cancer Immunotherapy Market Overview by Application
- Spanish Cancer Immunotherapy Market Overview by End-User

o Rest of Europe

- Rest of Europe Cancer Immunotherapy Market Overview by Product
- Rest of Europe Cancer Immunotherapy Market Overview by Application
- Rest of Europe Cancer Immunotherapy Market Overview by End-User

8. Asia-Pacific

- Asia-Pacific Cancer Immunotherapy Market Overview by Geographic Region
- Asia-Pacific Cancer Immunotherapy Market Overview by Product
- Asia-Pacific Cancer Immunotherapy Market Overview by Application
- Asia-Pacific Cancer Immunotherapy Market Overview by End-User
- Country-wise Analysis of Asia-Pacific Cancer Immunotherapy Market

o Japan

- Japanese Cancer Immunotherapy Market Overview by Product
- Japanese Cancer Immunotherapy Market Overview by Application
- Japanese Cancer Immunotherapy Market Overview by End-User

o China

- Chinese Cancer Immunotherapy Market Overview by Product
- Chinese Cancer Immunotherapy Market Overview by Application
- Chinese Cancer Immunotherapy Market Overview by End-User

o India

- Indian Cancer Immunotherapy Market Overview by Product
- Indian Cancer Immunotherapy Market Overview by Application
- Indian Cancer Immunotherapy Market Overview by End-User

o South Korea

- South Korean Cancer Immunotherapy Market Overview by Product
- South Korean Cancer Immunotherapy Market Overview by Application
- South Korean Cancer Immunotherapy Market Overview by End-User

o Rest of Asia-Pacific

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- Rest of Asia-Pacific Cancer Immunotherapy Market Overview by Product
- Rest of Asia-Pacific Cancer Immunotherapy Market Overview by Application
- Rest of Asia-Pacific Cancer Immunotherapy Market Overview by End-User

#### 9. South America

- South American Cancer Immunotherapy Market Overview by Geographic Region
- South American Cancer Immunotherapy Market Overview by Product
- South American Cancer Immunotherapy Market Overview by Application
- South American Cancer Immunotherapy Market Overview by End-User
- Country-wise Analysis of Asia-Pacific Cancer Immunotherapy Market

##### o□Brazil

- Brazilian Cancer Immunotherapy Market Overview by Product
- Brazilian Cancer Immunotherapy Market Overview by Application
- Brazilian Cancer Immunotherapy Market Overview by End-User

##### o□Argentina

- Argentine Cancer Immunotherapy Market Overview by Product
- Argentine Cancer Immunotherapy Market Overview by Application
- Argentine Cancer Immunotherapy Market Overview by End-User

##### o□Rest of South America

- Rest of South American Cancer Immunotherapy Market Overview by Product
- Rest of South American Cancer Immunotherapy Market Overview by Application
- Rest of South American Cancer Immunotherapy Market Overview by End-User

#### 10. Rest of World

- Rest of World Cancer Immunotherapy Market Overview by Product
- Rest of World Cancer Immunotherapy Market Overview by Application
- Rest of World Cancer Immunotherapy Market Overview by End-User

#### PART C: GUIDE TO THE INDUSTRY

#### PART D: ANNEXURE

##### 1. RESEARCH METHODOLOGY

##### 2. FEEDBACK

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

## Cancer Immunotherapy - A Global Market Overview

Market Report | 2024-11-05 | 256 pages | Industry Experts

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to [support@scotts-international.com](mailto:support@scotts-international.com)

### ORDER FORM:

Select license	License	Price
	Single user licence (PDF)	\$4500.00
	Enterprise Electronic (PDF)	\$7200.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact [support@scotts-international.com](mailto:support@scotts-international.com) or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-06-06"/>
		Signature	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)